What is the current valuation of Pfizer’s Dekavil
Dekavil is a fusion protein commercialized by Pfizer, with a leading Phase II program in Rheumatoid Arthritis. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 1 is ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Dekavil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Dekavil is expected to reach an annual total of $21 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Dekavil (F8-IL10) is under development for the treatment of rheumatoid arthritis. The drug candidate is administered intravenously, intraarticularly and subcutaneously as powder for solution. The drug candidate is a new biological entity (NBE). The drug candidate is an immuno-cytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10).
It was under development for the treatment of ulcerative colitis and crohn’s disease.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$100,330 million for the fiscal year ended December 2022 (FY2022), an increase of 23.4% over FY2021. The operating profit of the company was US$36,551 million in FY2022, compared to an operating profit of US$23,652 million in FY2021. The net profit of the company was US$31,372 million in FY2022, compared to a net profit of US$21,980 million in FY2021.
For a complete picture of Dekavil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
#current #valuation #Pfizers #Dekavil